• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by RxSight Inc.

    4/8/25 8:23:23 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    RxSight, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    78349D107

    (CUSIP Number)


    04/03/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    78349D107


    1Names of Reporting Persons

    Divisadero Street Capital Management, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,531,521.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,531,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,531,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    78349D107


    1Names of Reporting Persons

    William Zolezzi
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,531,521.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,531,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,531,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    78349D107


    1Names of Reporting Persons

    Divisadero Street Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,245,629.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,245,629.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,245,629.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    78349D107


    1Names of Reporting Persons

    Divisadero Street Partners GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,245,629.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,245,629.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,245,629.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    78349D107


    1Names of Reporting Persons

    Divisadero Street Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,531,521.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,531,521.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,531,521.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RxSight, Inc.
    (b)Address of issuer's principal executive offices:

    100 Columbia, Aliso Viejo, CA 92656
    Item 2. 
    (a)Name of person filing:

    Divisadero Street Capital Management, LP William Zolezzi Divisadero Street Partners, L.P. Divisadero Street Partners GP, LLC Divisadero Street Capital, LLC
    (b)Address or principal business office or, if none, residence:

    Divisadero Street Capital Management, LP 3480 Main Highway, Suite 204 Miami, FL 33133 William Zolezzi c/o Divisadero Street Capital Management, LP 3480 Main Highway, Suite 204 Miami, FL 33133 Divisadero Street Partners, L.P. 3480 Main Highway, Suite 204 Miami, FL 33133 Divisadero Street Partners GP, LLC 3480 Main Highway, Suite 204 Miami, FL 33133 Divisadero Street Capital, LLC 3480 Main Highway, Suite 204 Miami, FL 33133
    (c)Citizenship:

    Divisadero Street Capital Management, LP - Delaware William Zolezzi - United States Divisadero Street Partners, L.P. - Delaware Divisadero Street Partners GP, LLC - Delaware Divisadero Street Capital, LLC - Delaware
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    78349D107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Divisadero Street Capital Management, LP - 2,531,521 William Zolezzi - 2,531,521 Divisadero Street Partners, L.P. - 2,245,629 Divisadero Street Partners GP, LLC - 2,245,629 Divisadero Street Capital, LLC - 2,531,521
    (b)Percent of class:

    Divisadero Street Capital Management, LP - 6.3% William Zolezzi - 6.3% Divisadero Street Partners, L.P. - 5.5% Divisadero Street Partners GP, LLC - 5.5% Divisadero Street Capital, LLC - 6.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Divisadero Street Capital Management, LP - 0 William Zolezzi - 0 Divisadero Street Partners, L.P. - 0 Divisadero Street Partners GP, LLC - 0 Divisadero Street Capital, LLC - 0

     (ii) Shared power to vote or to direct the vote:

    Divisadero Street Capital Management, LP - 2,531,521 William Zolezzi - 2,531,521 Divisadero Street Partners, L.P. - 2,245,629 Divisadero Street Partners GP, LLC - 2,245,629 Divisadero Street Capital, LLC - 2,531,521

     (iii) Sole power to dispose or to direct the disposition of:

    Divisadero Street Capital Management, LP - 0 William Zolezzi - 0 Divisadero Street Partners, L.P. - 0 Divisadero Street Partners GP, LLC - 0 Divisadero Street Capital, LLC - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Divisadero Street Capital Management, LP - 2,531,521 William Zolezzi - 2,531,521 Divisadero Street Partners, L.P. - 2,245,629 Divisadero Street Partners GP, LLC - 2,245,629 Divisadero Street Capital, LLC - 2,531,521

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G are directly owned by advisory clients of Divisadero Street Capital Management, LP. None of those advisory clients, other than Divisadero Street Partners, L.P., may be deemed to beneficially own more than 5% of the Common Stock, $0.001 par value per share.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Divisadero Street Capital Management, LP
     
    Signature:By: /s/ William Zolezzi
    Name/Title:William Zolezzi/Manager
    Date:04/08/2025
     
    William Zolezzi
     
    Signature:By: /s/ William Zolezzi
    Name/Title:William Zolezzi
    Date:04/08/2025
     
    Divisadero Street Partners, L.P.
     
    Signature:By: /s/ William Zolezzi
    Name/Title:William Zolezzi/Manager
    Date:04/08/2025
     
    Divisadero Street Partners GP, LLC
     
    Signature:By: /s/ William Zolezzi
    Name/Title:William Zolezzi/Manager
    Date:04/08/2025
     
    Divisadero Street Capital, LLC
     
    Signature:By: /s/ William Zolezzi
    Name/Title:William Zolezzi/Manager
    Date:04/08/2025
    Exhibit Information

    [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

    Get the next $RXST alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    7/10/2025$9.00Buy → Hold
    Jefferies
    7/9/2025Outperform → Perform
    Oppenheimer
    7/9/2025$9.00Overweight → Equal Weight
    Wells Fargo
    7/9/2025Buy → Neutral
    BTIG Research
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    4/4/2025$40.00 → $17.00Overweight → Underweight
    Analyst
    More analyst ratings

    $RXST
    SEC Filings

    See more
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      7/8/25 4:10:29 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RxSight, Inc. (0001111485) (Filer)

      6/4/25 4:15:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by RxSight Inc.

      SD - RxSight, Inc. (0001111485) (Filer)

      5/20/25 4:30:10 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Link William J Phd was granted 10,752 shares, increasing direct ownership by 40% to 37,855 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      6/4/25 9:38:26 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Fountain Tamara was granted 10,752 shares, increasing direct ownership by 43% to 35,545 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      6/4/25 9:38:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Warner Robert Keith was granted 10,752 shares, increasing direct ownership by 36% to 41,039 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      6/4/25 9:37:34 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The

      7/8/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

      ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

      5/20/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RxSight downgraded by Jefferies with a new price target

      Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00

      7/10/25 8:36:38 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by Oppenheimer

      Oppenheimer downgraded RxSight from Outperform to Perform

      7/9/25 8:19:00 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded RxSight from Overweight to Equal Weight and set a new price target of $9.00

      7/9/25 8:18:49 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/14/24 7:14:14 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      5/21/24 4:11:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

      ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

      1/4/22 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/14/24 5:46:12 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 4:50:57 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 9:40:27 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Financials

    Live finance-specific insights

    See more
    • RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The

      7/8/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care